|
MaxCyte Inc on Wednesday posted a widened net loss of $19.1 million in 2021, increased from a loss of $11.8 million the year before.
Revenue increased by 30% to $33.9 million from $26.2 million.
The Maryland-based platform for cell-based research is expecting 2022 revenue from its core business to grow between 22% and 25% over 2021.
‘We continue to expand our customer base and increase the number of strategic partnerships, now with 16 strategic platform license agreements in place following the announcement of our agreement with Intima Bioscience in February 2022,’ Chief Executive Officer Doug Doerfler said.
MaxCyte shares closed 6.6% higher at 531.00 pence each in London on Wednesday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
